Stocks · Healthcare · Biotechnology
Humacyte, Inc. HUMA
$0.52 +3.70% Close, Oct 2, 2026 · NASDAQ · Market cap $87.6M
Weak trendExpensive vs sectorHigh risk
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $2.1M, down 73.6% from a year earlier.
- Operating margin narrowed to -5240.8% from -1382.5% a year earlier.
- The diluted share count rose 50.7% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 7%
- Revenue growth, 3-year CAGRBottom 47%
- Revenue growth accelerationTop 41%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 12%
- Gross marginBottom 3%
- Operating marginBottom 6%
- Accruals (lower is better)Bottom 17%
- Interest coverBottom 32%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 7%
- Free-cash-flow yieldBottom 2%
- EBITDA / enterprise valueBottom 5%
- Sales / enterprise valueBottom 14%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 2%
- 6-month returnBottom 25%
- 1-year return vs S&P 500Bottom 3%
- Distance from 52-week highBottom 3%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 36%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 26%
- Upside to consensus price targetTop 12%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 13%
- Maximum drawdown, 3 yearsBottom 6%
- Beta vs S&P 500 (lower is better)Bottom 1%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -74.0% | -73.6% | ↑ |
| Gross margin | -17.8% | -666.8% | ↓ |
| Operating margin | -1382.5% | -5240.8% | ↓ |
| FCF margin | -1321.0% | -4599.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -73.6% | -74.0% | ↑ | Bottom 7% |
| Gross margin | -666.8% | -17.8% | ↓ | Bottom 3% |
| Operating margin | -5240.8% | -1382.5% | ↓ | Bottom 6% |
| Net margin | -4560.8% | -729.1% | ↓ | — |
| Free-cash-flow margin | -4599.7% | -1321.0% | ↓ | — |
| Return on invested capital | -89.2% | — | Bottom 12% | |
| Revenue growth, 3-year CAGR | 9.2% | — | Bottom 47% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 0.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 504.9%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +57.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -10.8×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -163.69%
- Shareholder yield
- -163.69%
- Share count change, 1 year
- +50.7%
- Share count change, 3-year CAGR
- +31.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -3.3%
- Average 2-day reaction, last 8
- +1.4%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $2.00
- Target vs current price
- +283.5%
- Analysts with a rating
- 11
- Share rating Buy or Strong Buy
- 91%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | -41.0% | -6.3% | -18.1% | -18.5% | — |
| May 13, 2026 | +10.0% | +24.2% | -9.3% | +47.3% | -21.1% |
| Mar 27, 2026 | +0.0% | -13.2% | -17.5% | -10.1% | -10.0% |
| Nov 12, 2025 | +17.6% | -2.3% | -6.3% | -0.8% | -4.7% |
| Aug 11, 2025 | -60.0% | -29.4% | -24.2% | -43.1% | -35.9% |
| May 13, 2025 | +247.4% | +31.1% | +68.9% | +102.3% | +87.1% |
| Mar 28, 2025 | +33.3% | -2.5% | -27.9% | -28.4% | +10.9% |
| Nov 8, 2024 | -32.0% | +9.9% | -8.0% | -8.2% | -18.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.16 | -$0.11 | -41.0% | $406,000 |
| May 13, 2026 | -$0.09 | -$0.10 | +10.0% | $495,000 |
| Mar 27, 2026 | -$0.13 | -$0.13 | +0.0% | $467,000 |
| Nov 12, 2025 | -$0.14 | -$0.17 | +17.6% | $753,000 |
| Aug 11, 2025 | -$0.24 | -$0.15 | -60.0% | $301,000 |
| May 13, 2025 | $0.28 | -$0.19 | +247.4% | $517,000 |
| Mar 28, 2025 | -$0.16 | -$0.24 | +33.3% | $7.2M |
| Nov 8, 2024 | -$0.33 | -$0.25 | -32.0% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 34.84× | — | — | Bottom 14% |
| Free-cash-flow yield | -111.35% | — | — | Bottom 2% |
| Earnings yield | -97.60% | — | — | Bottom 7% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -8.1%
- 200-day average slope (20 days)
- -7.4%
- Distance from 50-day average
- -15.6%
- Distance from 200-day average
- -40.3%
- RSI (14)
- 37.5
- Relative volume
- 1.53×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 87.5%
- Volatility vs own 5-year history
- 41th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 3.28
- Correlation with S&P 500
- 0.45
- Current drawdown from 1-year high
- -79.0%
- Maximum drawdown, 3 years
- -94.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 1, 2021 | Oct 1, 2026 | -97.0% | 1275 days | Not yet recovered |
| Feb 22, 2021 | Aug 19, 2021 | -38.5% | 125 days | 9 days (Sep 1, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $87.6M
- EPS, diluted (TTM)
- -$0.51
- Revenue (TTM)
- $2.1M
- 52-week range
- $0.50 – $2.55
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.3M | $1.6M | $0 | $0 | $2.0M |
| Gross profit | -$60.1M | -$6.7M | -$76.5M | -$7.2M | -$15.0M |
| Operating income | -$81.2M | -$84.6M | -$100.0M | -$114.4M | -$107.4M |
| Net income | -$26.5M | -$12.0M | -$110.8M | -$148.7M | -$40.8M |
| EPS (diluted) | -$0.66 | -$0.12 | -$1.07 | -$1.26 | -$0.26 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $7.2M | $517,000 | $301,000 | $753,000 | $467,000 | $495,000 | $406,000 |
| Net income | -$39.2M | -$20.9M | $39.1M | -$37.7M | -$17.5M | -$24.8M | -$17.6M | -$36.8M |
| EPS (diluted) | -$0.33 | -$0.16 | $0.28 | -$0.24 | -$0.11 | -$0.15 | -$0.09 | -$0.16 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$81.2M | -$71.1M | -$73.3M | -$98.1M | -$105.0M |
| Capital expenditure | -$220,000 | -$1.0M | -$2.3M | -$1.6M | -$884,000 |
| Free cash flow | -$81.4M | -$72.2M | -$75.6M | -$99.7M | -$105.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $598,000 | $535,000 | $566,000 | $45.9M | $113.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $79.9M
- Total assets
- $138.1M
- Total liabilities
- $106.8M
- Total debt
- $66.2M
- Net debt
- -$13.7M
- Shareholders’ equity
- $31.3M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 31,807,566
- Days to cover
- 7.25
- Change vs previous report
- +6.7%
FINRA short interest, settlement date Sep 15, 2026.